Trapani, D.; Tay-Teo, K.; Tesch, M.E.; Roitberg, F.; Sengar, M.; Altuna, S.C.; Hassett, M.J.; Genazzani, A.A.; Kesselheim, A.S.; Curigliano, G.
Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments. Curr. Oncol. 2022, 29, 5774-5791.
https://doi.org/10.3390/curroncol29080455
AMA Style
Trapani D, Tay-Teo K, Tesch ME, Roitberg F, Sengar M, Altuna SC, Hassett MJ, Genazzani AA, Kesselheim AS, Curigliano G.
Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments. Current Oncology. 2022; 29(8):5774-5791.
https://doi.org/10.3390/curroncol29080455
Chicago/Turabian Style
Trapani, Dario, Kiu Tay-Teo, Megan E. Tesch, Felipe Roitberg, Manju Sengar, Sara C. Altuna, Michael J. Hassett, Armando A. Genazzani, Aaron S. Kesselheim, and Giuseppe Curigliano.
2022. "Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments" Current Oncology 29, no. 8: 5774-5791.
https://doi.org/10.3390/curroncol29080455
APA Style
Trapani, D., Tay-Teo, K., Tesch, M. E., Roitberg, F., Sengar, M., Altuna, S. C., Hassett, M. J., Genazzani, A. A., Kesselheim, A. S., & Curigliano, G.
(2022). Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments. Current Oncology, 29(8), 5774-5791.
https://doi.org/10.3390/curroncol29080455
